This study has 8 locations in USA - 11 Dec `20Evaluation of AMG 714 for Vitiligo (REVEAL)

Official title: Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI)

The AMG 714 for Vitiligo (REVEAL Trial), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), is a Phase 2 clinical study evaluating the efficacy and safety of AMG 714, an anti-IL-15 monoclonal antibody, in adults with vitiligo. The trial aims to determine if AMG 714, combined with narrowband ultraviolet B (nbUVB) phototherapy, can effectively restore skin pigmentation by modulating the immune response responsible for melanocyte destruction.

This is an active study which is not recruiting new patients.

 

Start date: 2020-12-11

Completion date: 2025-05-30

Contact: Brett A. King, MD, PhD

Tel.:

Email:

Link: https://clinicaltrials.gov/study/NCT04338581

Clinical Trials Alerts

Sign up and be the first to know when new trials are starting nearby.



FAQOther Questions

  • Can chemicals cause vitiligo?

    Certain chemicals can trigger vitiligo, leading to a condition known as chemical-induced vitiligo. While clinically and histologically indistinguishable from other types of viti...

  • Which therapy has minimal side-effects?

    Dead Sea climatotherapy is a unique and highly effective treatment option for vitiligo, offering a top-tier safety profile and natural therapeutic benefits. Its combination of p...

  • Pyrostegia venusta as a folk medicine for vitiligo?

    Pyrostegia venusta, also known as “flame vine” or “cipó-de-são-joão,” is a neotropical evergreen vine native to Brazil. It thrives in fields, coastal areas, forest edges, and ro...